North America Continuous Glucose Monitoring Systems (CGMS) Market (2016-2022)
The Continuous Glucose Monitoring Systems (CGMS) devices have witnessed continuous technological evolution CGMS with smartphone connectivity. Wearable CGMS is another promising product with tremendous potential within the wearable healthcare devices. Non-invasive CGMS such as Symphony CGM System, due to its user-friendliness, extensive applications and FDA approvals for the same, have gained prominence over the years. Bionic pancreas is another notable product which is a smart and a complete diabetes management solution which is majorly used for Type I diabetes patients, is another notable breakthrough within the CGMS market.
The component segment of the CGMS market includes transmitters and receivers, sensors and CGMS compatible insulin pumps. Sensors market was the major segment with largest market share in 2015 and is anticipated to register a CAGR of 39% during the forecast period.
The report highlights the adoption of Continuous Glucose Monitoring Systems (CGMS) in North America. Based on the Component, the Global Continuous Glucose Monitoring Systems Market is segmented into Sensors, Transmitters & Receivers and Integrated Insulin pumps segment. Based on the End user, the market is bifurcated into Diagnostic centers/clinics, ICUs and Home Healthcare segments. The countries included in the report are U.S, Canada, Mexico and Rest of North America region.
Key Players profiled in the report includes Roche Diagnostics, Abbott Laboratories, Dexcom Inc., Novo Nordisk, Ypsomed AG, GlySens Incorporated, Medtronic Plc and Johnson & Johnson.